OPT

Opthea Limited

1 day chart

About OPT

Opthea Limited (OPT) develops and commercialise therapies primarily for eye disease. Opthea's lead asset, OPT -302, is a soluble form of VEGFR-3 in clinical development as a novel therapy for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The Group operates in one industry and one geographical area, those being the biotechnology and healthcare industry and Australia.

Buy Australian shares starting with OPT. Invest today with a CHESS-sponsored investing platform!

Sector

Health Care

CEO

Industry

Biotechnology

Website

opthea.com

Market Capitalisation

$212M

Price-earnings ratio

-0.66

Dividend yield

NaN%

High today

$0.36

Low today

$0.33

Open price

$0.36

52-week high

$1.13

52-week low

$0.32

Announcements

OPT FAQs

Can I buy OPT shares through Stake, an investing platform like CommSec, Selfwealth or Superhero?

Yes, the Stake platform allows you to buy OPT shares and over 8,000 stocks and ETFs across the ASX and Wall St.

How much is one share of Opthea Limited?

One share of Opthea Limited is valued at $0.34.

What is the ticker symbol for Opthea Limited?

The ticker symbol for Opthea Limited is OPT.

How do I buy OPT shares in Australia?

To buy OPT stocks in Australia you'll need to open an account with an investing platform like Stake.
To do so follow these steps:

Sign up in minutes, all you need is some I.D.
Choose Stake AUS
Deposit directly into your Stake wallet and you're ready to invest in OPT

What is the 52-week high for Opthea Limited stock?

The Opthea Limited 52-week high stock price is $1.13.

What is the 52-week low for Opthea Limited stock?

The Opthea Limited 52-week low stock price is $0.32.

What is the market capitalisation of Opthea Limited OPT?

As of 26/09/2023 Opthea Limited has a market cap of $212M.

Related Stocks

This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.